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ABSTRACT 
 
 
Kynurenic acid is an astrocyte-derived tryptophan metabolite and a marker of 
neuroinflammation that antagonizes N-metyl-D-aspartate (NMDA) and α7 nicotinic 
acetylcholine receptors in the brain. Increased levels have been found in the 
cerebrospinal (CSF) and brains of patients with schizophrenia and experimental studies 
have shown that kynurenic acid bi-directionally influences dopaminergic 
neurotransmission. Hyperdopaminergia is suggested to underlie positive symptoms of 
schizophrenia and symptoms of mania/psychosis in bipolar disorder. Consistent with 
this notion, patients with schizophrenia show excessive amphetamine-induced 
dopamine release that correlates with the degree of positive symptoms. Further, patients 
with bipolar disorder show augmented amphetamine-induced behavioral response 
compared to controls. Here we examine the effects of elevated brain kynurenic acid on 
amphetamine-induced dopamine transmission, as well as the CSF content of kynurenic 
acid and cytokines in patients with bipolar disorder, in order to investigate their putative 
involvement in schizophrenia and bipolar disorder pathophysiology. 
Accumbal dopamine release and ventral tegmental area (VTA) dopamine firing in 
response to amphetamine (2 mg/kg, i.p. or 0.2-25.6 mg/kg, i.v.) was measured by in 
vivo microdialysis with HPLC electrochemical detection and electrophysiology 
techniques. Sprague Dawley rats were treated with acute or subchronic L-kynurenine (5 
mg/kg, s.c. or 90 mg/kg/day, s.c., for six days via osmotic minipumps) to elevate brain 
kynurenic acid levels. For locomotor activity experiments, C57BL/6 mice received 
acute or subchronic pretreatment of L-kynurenine (10 mg/kg, i.p. or 100 mg/kg, i.p., 
twice daily for six days). Spontaneous and amphetamine-induced (5 mg/kg, i.p.) 
locomotor activity was tested in a square open field arena. 
The acute elevation of brain kynurenic acid resulted in increased anxiety-related 
behavior. Subchronic elevation of brain kynurenic acid produced an exaggerated 
amphetamine-induced accumbal dopamine release in the rat and increased locomotor 
activity in the mouse. These results might be related to the impaired amphetamine-
induced feedback inhibition of VTA dopamine firing observed following subchronic 
elevation of brain kynurenic acid. Present results confirm that kynurenic acid modulates 
dopamine neurotransmission and behavior in rodents and that subchronic elevation of 
kynurenic acid is associated with dopaminergic changes that are consistent with 
findings in patients with schizophrenia or bipolar disorder. 
Analysis of CSF showed increased levels of kynurenic acid and IL-1β,	   and	  
decreased levels of IL-6 in patients with bipolar disorder. Positive correlations were 
found between the occurrence of recent symptoms of mania and the levels of IL-1β or 
kynurenic acid. Further, the lifetime occurrence of psychotic symptoms was associated 
with higher levels of kynurenic acid. Although causality needs to be determined, these 
results may suggest a pathophysiological role for IL-1β and kynurenic acid in 
psychiatric disorders involving symptoms of mania and psychosis. Given the present 
experimental results, prolonged elevation of brain kynurenic acid, possibly induced by 
increased levels of pro-inflammatory IL-1β, may cause a hyperdopaminergic state that 
drives symptoms of mania and/or psychosis. The positive correlation between CSF 
kynurenic acid and the dopamine metabolite homovanillic acid found in these patients 
further favor this idea. 
 
